Isolation, Culture, and Functional Characterization of Human Embryonic Stem Cells: Current Trends and Challenges

Firdos Alam Khan, Dana Almohazey, Munthar Alomari, and Sarah Ameen Almofty

Department of Stem Cell Biology, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Post Box No. 1982, Dammam 31441, Saudi Arabia

Correspondence should be addressed to Firdos Alam Khan; fakhan@iau.edu.sa

Received 19 April 2018; Revised 19 July 2018; Accepted 30 July 2018; Published 26 August 2018

Academic Editor: Valeria Sorrenti

Copyright © 2018 Firdos Alam Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human embryonic stem cells (hESCs) hold great potential for the treatment of various degenerative diseases. Pluripotent hESCs have a great ability to undergo unlimited self-renewal in culture and to differentiate into all cell types in the body. The journey of hESC research is not that smooth, as it has faced several challenges which are limited to not only tumor formation and immunorejection but also social, ethical, and political aspects. The isolation of hESCs from the human embryo is considered highly objectionable as it requires the destruction of the human embryo. The issue was debated and discussed in both public and government platforms, which led to banning of hESC research in many countries around the world. The banning has negatively affected the progress of hESC research as many federal governments around the world stopped research funding. Afterward, some countries lifted the ban and allowed the funding in hESC research, but the damage has already been done on the progress of research. Under these unfavorable conditions, still some progress was made to isolate, culture, and characterize hESCs using different strategies. In this review, we have summarized various strategies used to successfully isolate, culture, and characterize hESCs. Finally, hESCs hold a great promise for clinical applications with proper strategies to minimize the teratoma formation and immunorejection and better cell transplantation strategies.

1. Embryonic Stem Cells: Early Discovery and Isolation Procedure

Embryonic stem cells (ESCs) were first isolated from mouse embryos in 1981, and the word “embryonic stem cell” was first coined by Gail R. Martin. Nonetheless, the world came to know about ESCs with the breakthrough discovery in 1998, where Thomson and his team showed for the first time a technique to isolate hESCs from human embryos. Thereafter, researchers have demonstrated that hESCs have an ability to differentiate into all body cells, including beta cells of the islets of Langerhans [1], neural cells [2], cardiomyocytes [3], and hepatocyte-like cells [4]. The pluripotent capabilities of hESCs have given hope to millions of patients who are suffering from diabetes, Parkinson’s disease, cardiovascular disease, and liver diseases. Considering hESCs having great therapeutic potentials, several hESC lines were generated across the world. One of the challenges of the hESCs was the method of isolation of stem cells from the human embryo, as hESCs can only be obtained from the inner cell mass (ICM) of human embryos [5]. Researchers reported that ICM can be obtained from either fresh or frozen human embryos [5–7]. Thereafter, several methods were developed to isolate ICM from a single human embryo, which include mechanical dissection, where ICM is isolated by mechanical pressure [6, 7]. The ICM can also be isolated by using laser dissection [8, 9] and by using immunosurgery procedures [10–12]. There are various benefits of using an immunosurgery procedure to isolate ICM, but this also carries some disadvantages. For example, the immunosurgery procedure requires the culture media which contain guinea pig serum; hence, the use of animal serum makes the immunosurgery technique not suitable for the generation of clinical-grade hESC lines [13]. In another method, hESC lines can be isolated from ICM by microdissection of human blastocysts using fine needles. Laser-assisted biopsy is also the most
promising technique for xeno-free isolation of the ICM [9, 14]. After ICM isolation, the stems cells are grown to generate the ESCs using feeder layers, extracellular matrices, proteins, peptides, and synthetic polymers [9, 14]. Advantages and disadvantages of various methods of ICM isolation are summarized in Table 1.

The isolation of ICM requires destruction of human embryos which has raised serious ethical concerns [15]. To satisfy the ethical issue, researchers demonstrated an alternate approach to isolate hESCs from a single blastomere without killing or destroying the human embryo. For example, during preimplantation genetic testing, embryo biopsy carrying a single blastomere can be obtained from patients ([16, 17]; Klimanskaya et al., 2009). It has been reported that 5 hESC lines were successfully obtained from a single blastomere biopsy [16]. The success of obtaining good-quality hESCs depends on the quality of blastocysts and isolation procedures and culture conditions. It was reported that 2 hESC lines were obtained from 4 blastocysts, whereas only 3 hESC lines could be isolated from 13 blastocysts and, in some cases, only 3 hESC lines could be isolated from 58 blastocysts [13]. These differences in isolation of hESC lines from different blastocysts are mainly due to the quality of embryos and also depend on the method of embryo isolation and culture protocols [18, 19]. For example, if an embryo is obtained through an in vitro fertilization method, then there is a great possibility that embryos will have a high incidence of postzygotic chromosomal abnormalities which may eventually give poor quality of hESCs [13].

In mice, pluripotent stem cells can also be derived from the epiblast of post-implantation-stage embryos, commonly known as epiblast stem cells. These pluripotent stem cells show primed characteristics and are highly dependent upon the activation of FGF and activin signalling pathways for their self-renewal [20, 21]. Consequently, three distinct pluripotent conditions, namely, naive, primed, and ground pluripotency conditions, have been defined in mice [22].

2. Culturing of hESCs with or without Feeder Cells

Once the blastomere is collected, it is normally cocultured with the parental biopsy embryo in the medium containing fibronectin and laminin. The addition of serum-free media and fibroblast growth factors enhance stem cell proliferation and prevent embryonic stem cells from undergoing differentiation [23, 24]. We have briefly described various culture conditions which have been used to improve both quality and quantity of generation of hESCs.

2.1. Mouse Feeder Cells to Grow hESCs. Mouse embryonic fibroblast (MEF) cells or mouse feeder cells are considered most important elements for hESCs because MEF provides favorable condition for growth and expansion of hESCs (Figure 1). It has been reported that MEFs are very important for the successful generation of hESC lines [11, 12]. In addition, all early hESC lines were grown in the media containing growth factors and cytokines secreted by MEF cells, and these growth factors and cytokines are necessary to maintain the pluripotency of the stem cells. As MEF was derived from a mouse source, it has posed serious ethical or health issues for hESCs. Moreover, the use of animal-based cells can transmit animal-derived infectious pathogens to hESCs and make them not suitable for human utilization. It has been reported that MEF cells contain viral particles that are capable of infecting hESCs during culture [25]. Furthermore, some
Among these human cells, human umbilical stromal cells, placental cells [36, 37], and endometrial cells [36, 38, 39] have been reported to support the growth and expansion of embryonic stem cells [33], bone marrow [34], umbilical cord [35], foreskin [31], fetal muscle and skin [32], transgenic fetal liver [30], fetal fallopian tube cells [29]. It has been reported that human cells can be used for hESC culture media up to 80 passages [40, 41]. Moreover, hESCs were also grown in xeno-free culture media up to 80 passages [40, 41].

Undoubtedly, the use of chemically defined media along with proteins has significantly improved the culture of hESCs. In addition, different proteins and recombinant proteins were also used to enhance hESC culture under xeno-free condition. Among those were E-cadherin, E-cadherin/laminin 521, and kinase inhibitors along with bFGF which are known to cause robust proliferation of stem cells under xeno-free conditions [54]. Synthetically designed bed surface was also used to stimulate stem cell culture (Melkoumian et al., 2010); for example, Corning Synthemax Surface, a synthetic acrylate surface conjugated with vitronectin, was shown to enhance not only hESC colonies but also expansion of stem cells (Kawase et al., 2014). Wu et al. recently described the use of novel synthetic material isolated from spider silk proteins as a suitable substrate to stimulate hESC culture (Wu et al., 2014). Numerous polymer-based synthetic surfaces have been also reported to support the growth and expansion of hESC lines (Melkoumian et al., 2010; Brafman et al., 2010; Villa-Diaz et al., 2013). The list of different chemicals used to enhance culture of hESCs is shown in Table 2.

3. Multilineage Potential of hESCs

One of the utmost characteristics of hESCs is to differentiate into all three lineages such ectoderm, mesoderm, and endoderm (Figure 3). As hESCs are pluripotent stem cells, they have unique capabilities to differentiate into all kinds of body cells; for example, hESCs can be differentiated into neurons, cardiac cells, hepatocytes, and muscle cells. It has been reported that hESCs first form embryo bodies which are basically structured with three germ layers. These embryo bodies are formed by pluripotent hESCs grown in 3-
dimensional (3D) culture and expressed genetic markers for all three germ layers [55–57]. Pluripotent hESCs have a tremendous ability to differentiate (Table 3) into adrenal cells and keratinocytes [58], insulin-producing cells [59], neuronal cells [60, 61], cardiac cells [62], liver cells [63], and islet-like organoid [64]. Certain growth factors such as retinoic acid and nerve growth factors are being used to induce hESCs to differentiate into functional neurons. Moreover, some lineage-specific growth factors are being used for the differentiation into cardiomyocytes, hepatocytes, skeletal muscles, pancreatic cells, and kidney cells. These differentiated cells are also being tested for examining their functionality in both in vitro and in vivo conditions. This multilineage potential of hESCs has proved to be vital for cell-based therapy to treat different degenerative diseases. While it is easy to differentiate different types of cells from hESCs, it is difficult to get a large number of differentiated mature cells for therapeutic applications [65]. To obtain large, mature, and functional differentiated cells, the culture media should contain lineage-specific growth factors. It is also important to generate large quantities of cells from hESCs as they are required for cell transplantation, and this can be achieved by culturing the hESCs and differentiated cells in a bioreactor under control condition [66].

4. Testing of hESCs Using In Vitro and In Vivo Models

After a successful differentiation of hESCs into various cell types, the next logical step is to examine whether derived differentiated cells have some functionality or not. The functionality of stem cells and differentiated precursor or mature cells was examined extensively in both in vitro and in vivo conditions. The functionality of differentiated neurons, cardiomyocytes, hepatocytes, and other types of cells was tested in various animal models [67]. It was found that transplantation of neurons in the animal model of Parkinson’s disease caused a partial recovery of the function [68, 69]. The transplantation of hESCs and their differentiated cells was tested in the animal models of cardiovascular disease, stroke, diabetes, and spinal cord injury [67]. Among animals, small rodents such as rats and mice have been a species of choice to study cell transplantation. Moreover, small rodents are effortlessly accessible and can be easily manipulated both surgically and genetically. Despite various benefits of small rodents, the ability of mouse/rat experiments to predict the efficacy of stem cell-based therapy remains contentious [70] as many mouse/rat models do not represent human disease phenotypes. To overcome this issue, researchers have started working on the large animals which are close to human anatomy and physiology. Among large animals, dogs, goats, sheep, and nonhuman primates are considered better models than mice/rats for the stem cell testing [70]. One of the main advantages of using large animals is their longer life span, and many anatomical, physiological parameters are much closer to humans [70]. Though these animal models demonstrate the effective delivery of stem cells in the host tissues, the complete functional and behavioral recovery is still not achieved. Further research is required to develop animal models which are close to human disease.

Despite this progress in hESC research, one important challenge of hESC-based cell therapy is the allogeneic
immune rejection of hESC-derived cells by recipients [71]. It was found that within a week, all the transplanted stem cells died due to the strong host immune response generated in animals. To stop the death of the transplanted stem cells, animals were injected with immunosuppressors to suppress the immunity triggered by stem cell transplantation. Surprisingly, when the animals were given immunosuppressors or drugs like tacrolimus and sirolimus, the hESCs could survive only for 28 days and started dying thereafter [72]. While we do not know the reason for this, a lack of understanding of cell-cell interaction could be one of the reasons. It is important to test hESCs or differentiated cells under in vitro conditions prior to animal testing. In vitro models provide better opportunities to study the cell-cell interaction, cell migration, or cell integration with a great detailed manner, which perhaps is very difficult to study in the animals. This problem could be mitigated by a recent breakthrough in the technology of induced pluripotent stem cells (iPSCs) by nuclear reprogramming of patient-specific somatic cells with defined factors, which could become a renewable source of autologous cells for cell therapy. One key advantage of iPSCs for human cell therapy is that patient-specific iPSCs are autologous, and, therefore, it has been assumed that the cells derived from them can be transplanted into the same patient without concerns over immune rejection [71]. However, recent studies revealing the abnormal epigenetics, genomic stability, and immunogenicity of iPSCs have raised safety concerns over iPSC-based therapy [73, 74].

5. Therapeutic Applications of hESCs

As hESCs hold a lot of promises for the patients who are suffering from degenerative diseases, various attempts have been made to explore the therapeutic potentials in humans. The main objective of stem cell-based therapy is to restore or repair the lost or damaged body cells or tissues. To make hESCs suitable for clinical applications, the derived stem cells must be manufactured as per United States Food Drug Administration (USFDA), Current Good Manufacturing Practices (cGMP), and Guidelines for the Clinical Transplantation of Stem Cells, respectively [75]. The chemicals, reagents, cells, and machines and instrumentation used in the stem cell culture should undergo safety and health checks, and all manufacturing processes must be monitored and documented as per cGMP guidelines. If we analyze how many currently used hESC lines comply with the cGMP guidelines, you will find that many of the hESC lines will fail to meet the cGMP guidelines, because many hESCs are exposed to immunogenic or pathogenic animal components during their isolation and propagation stages. Another reason for failing to meet the cGMP guidelines is that most of hESC culture works were conducted in a university’s laboratories, wherein many of these research laboratories do not comply with the cGMP guidelines. Till today, only a few researchers could be able to produce hESC lines as per the cGMP guidelines [14, 76, 77].

Considering potential commercial benefits of hESCs, few biotechnology companies were also involved in funding the stem cell research with a sole aim of commercializing stem cell products. These companies have started manufacturing hESCs under cGMP conditions and started testing stem cells under clinical setting. In 2009, Geron Corporation (California-based biotechnology company) applied to FDA to start its first clinical trial using cells derived from hESCs. The clinical trial was started in October 2010, where 3 patients who were suffering from spinal injury were injected with 1.5 million oligodendrocyte precursor cells derived from hESCs [78]. The trial was unexpectedly discontinued and we do not know the reason, probably because preliminary results of the trial showed that the cells derived from hESCs did not result in any noticeable improvement in spinal injury. In addition, the FDA also approved another trial for the use of hESCs in macular degeneration disease [79–85]. Another company, Advanced Cell Technology located in Marlborough, Massachusetts, started clinical trials using hESCs. The cells were injected in the patients who were suffering from Stargardt’s muscular dystrophy and from age-related dry macular degeneration. The retinal pigment epithelial (RPE) cells derived from hESCs were used [83]. In the study, RPE cells were administered in the patients, and after 4 months of posttransplantation, it was found that patients showed minor improvements in visual function without any indication of immune rejection or any sign of teratoma formation [83]. Stem cells were also tested in patients with type I diabetes, where pancreatic precursor cells were administered to the patients [86].

6. Summary and Conclusion

Human embryonic stem cells have great therapeutic potentials for the treatment of various diseases such as cancer, Parkinson’s disease, Alzheimer’s disease, and diabetes. Both in vitro and in vivo studies suggest that there is still hope that future embryonic stem cells will provide cures for various diseases. But the success of stem cell-based therapy depends on the availability of mature and functional cells. To obtain mature and functional cells, it would be better if stem cells are grown under three-dimensional (3D) culture condition. Most of the hESC lines are obtained through two-dimensional (2D) culture conditions. There are a few limitations of using 2D culture, as hESCs which have grown in 2D condition do not represent human cells of the human body and most of the 2D cultured hESCs are reported to die immediately after cell transplantation; those cells that survived still fail to repair the body tissues. This issue can be handled, by culturing hESCs in 3D conditions, where cells can grow in three directions and chances of cell survivability will enhance after cell transplantation. Another important point to consider for successful stem cell-based therapy is to rigorously evaluate stem cell-derived cells in animal models before testing in humans. The cell-cell integration, cell-cell communication, cell migration, and cell functionality need to be evaluated thoroughly in animal models using both short-term and long-term trial approaches. The issue related to trauma formation and immunorejection must also be resolved by developing stem cell lines which do not cause immunorejection and do not form tumor after transplantation. This can be achieved by silencing the gene/molecular
pathways which trigger tumor formation and immunorejection, respectively. Moreover, the cell-based therapy also demands many mature cells, and efforts should also be directed towards isolation of large quantity of stem cells and their precursors by bringing a new innovative approach and methodology. Finally, human embryonic stem cells still hold a great promise for the treatment of various degenerative diseases as well as diagnostic applications.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
This manuscript is approved by all authors for submission.

Acknowledgments
The authors are thankful to the entire management of the Institute for Research and Medical Consultations (IMRC), Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia, for their support and encouragement.

References
[1] H. Baharvand, H. Jafari, M. Massumi, and S. K. Ashtiani, “Generation of insulin-secreting cells from human embryonic stem cells,” Development, Growth & Differentiation, vol. 48, no. 5, pp. 323–332, 2006.
[2] M. Sundberg, P. H. Andersson, E. Åkesson et al., “Markers of pluripotency and differentiation in human neural precursor cells derived from embryonic stem cells and CNS tissue,” Cell Transplantation, vol. 20, no. 2, pp. 177–192, 2011.
[3] R. Pal, M. K. Mamidi, A. K. Das, and R. Bhonde, “Comparative analysis of cardiomyocyte differentiation from human embryonic stem cells under 3-D and 2-D culture conditions,” Journal of Bioscience and Bioengineering, vol. 115, no. 2, pp. 200–206, 2013.
[4] T. Miki, A. Ring, and J. Gerlach, “Hepatic differentiation of human embryonic stem cells is promoted by three-dimensional dynamic perfusion culture conditions,” Tissue Engineering Part C: Methods, vol. 17, no. 5, pp. 557–568, 2011.
[5] P. Loser, J. Schirm, A. Guhr, A. M. Wobus, and A. Kurtz, “Human embryonic stem cell lines and their use in international research,” Stem Cells, vol. 28, no. 2, pp. 240–246, 2010.
[6] G. Meng, S. Liu, X. Li, R. Krawetz, and D. E. Rancourt, “Derivation of human embryonic stem cell lines from blastocyst microsurgery,” Biochemistry and Cell Biology, vol. 88, no. 3, pp. 479–490, 2010.
[7] S. Strom, J. Inzunza, K. H. Grinnemo et al., “Mechanical isolation of the inner cell mass is effective in derivation of new human embryonic stem cell lines,” Human Reproduction, vol. 22, no. 12, pp. 3051–3058, 2007.
[8] N. Tanaka, T. Takeuchi, Q. V. Neri, E. S. Sills, and G. D. Palermo, “Laser-assisted blastocyst dissection and subsequent cultivation of embryonic stem cells in a serum/cell free culture system: applications and preliminary results in a murine model,” Journal of Translational Medicine, vol. 4, no. 1, p. 20, 2006.
[9] T. Turatsky, E. Aizenman, Y. Gil et al., “Laser-assisted derivation of human embryonic stem cell lines from IVF embryos after preimplantation genetic diagnosis,” Human Reproduction, vol. 23, no. 1, pp. 46–53, 2008.
[10] C. A. Cowan, I. Klimanskaya, J. McMahon et al., “Derivation of embryonic stem-cell lines from human blastocysts,” New England Journal of Medicine, vol. 350, no. 13, pp. 1353–1356, 2004.
[11] B. E. Reubinoff, M. F. Pera, C.-Y. Fong, A.Trounson, and A. Bongso, “Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro,” Nature Biotechnology, vol. 18, no. 4, pp. 399–404, 2000.
[12] J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., “Embryonic stem cell lines derived from human blastocysts,” Science, vol. 282, no. 5391, pp. 1145–1147, 1998.
[13] N. Desai, P. Rambhia, and A. Gishto, “Human embryonic stem cell cultivation: historical perspective and evolution of xenofree culture systems,” Reproductive Biology and Endocrinology, vol. 13, no. 1, p. 9, 2015.
[14] S. E. Tannenbaum, T. T. Turatsky, O. Singer et al., “Derivation of xenofree and GMP-grade human embryonic stem-cell platforms for future clinical applications,” PLoS One, vol. 7, no. 6, article e35325, 2012.
[15] M. H. Johnson, “Human ES cells and a blastocyst from one embryo: exciting science but conflicting ethics?,” Cell Stem Cell, vol. 2, no. 2, pp. 103–104, 2008.
[16] Y. Chung, I. Klimanskaya, S. Becker et al., “Human embryonic stem cell lines generated without embryo destruction,” Cell Stem Cell, vol. 2, no. 2, pp. 113–117, 2008.
[17] I. Klimanskaya, Y. Chung, S. Becker, S. J. Lu, and R. Lanza, “Human embryonic stem cell lines derived from single blastomers,” Nature, vol. 444, no. 7118, pp. 481–485, 2006.
[18] A. Galan, P. Diaz-Gimeno, M. E. Poo et al., “Defining the genomic signature of totipotency and pluripotency during early human development,” PLoS One, vol. 8, no. 4, article e62135, 2013.
[19] G. Giritharan, D. Ilic, M. Gormley, and A. Krtolica, “Human embryonic stem cells derived from embryos at different stages of development share similar transcription profiles,” PLoS One, vol. 6, no. 10, article e26570, 2011.
[20] I. G. M. Brons, L. E. Smithers, M. W. B. Trotter et al., “Derivation of pluripotent epiblast stem cells from mammalian embryos,” Nature, vol. 448, no. 7150, pp. 191–195, 2007.
[21] P. J. Tesar, J. G. Chenoweth, F. A. Brook et al., “One-stage derivation of pluripotent epiblast stem cells from mammalian embryos,” Nature, vol. 448, no. 7150, pp. 191–195, 2007.
[22] S. Ghimire, M. van der Jeught, J. Neupane et al., “Comparative analysis of naive, primed and ground state pluripotency in mouse embryonic stem cells originating from the same genetic background,” Scientific Reports, vol. 8, no. 1, p. 5884, 2018.
[23] M. Amit, M. K. Carpenter, M. S. Inokuma et al., “Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture,” Developmental Biology, vol. 227, no. 2, pp. 271–278, 2000.
[24] I. Klimanskaya, Y. Chung, L. Meisner, J. Johnson, M. D. West, T. Miki, A. Ring, and J. Gerlach, “Hepatic differentiation of human embryonic stem cells derived from early human development, sharing similar transcription profiles,” Nature, vol. 448, no. 7150, pp. 196–199, 2007.
[25] I. Palermo, “Laser-assisted blastocyst dissection and subsequent cultivation of embryonic stem cells in a serum/cell free culture system: applications and preliminary results in a murine model,” Journal of Translational Medicine, vol. 4, no. 1, p. 20, 2006.
fibroblasts but neither in human embryonic fibroblasts nor in human mesenchymal cells used for hESC maintenance: toward an implementation of microbiological quality assurance program in stem cell banks,” *Cloning and Stem Cells*, vol. 10, no. 1, pp. 65–74, 2008.

[26] C. A. Llewelyn, P. E. Hewitt, R. S. Knight et al., “Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion,” *Lancet*, vol. 363, no. 9407, pp. 417–421, 2004.

[27] I. Kubikova, H. Konecna, O. Sedo et al., “Proteomic profiling of human embryonic stem cell-derived microvesicles reveals a risk of transfer of proteins of bovine and mouse origin,” *Cytotherapy*, vol. 11, no. 3, pp. 330–340, 2009.

[28] J. Ratajczak, K. Miekus, M. Kucia et al., “Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery,” *Leukemia*, vol. 20, no. 5, pp. 847–856, 2006.

[29] M. J. Martin, A. Muotri, F. Gage, and A. Varki, “Human embryonic stem cells express an immunogenic nonhuman sialic acid,” *Nature Medicine*, vol. 11, no. 2, pp. 228–232, 2005.

[30] A. Bongso, C. Y. Fong, S. C. Ng, and S. Ratnam, “Isolation and culture of inner cell mass cells from human blastocysts,” *Human Reproduction*, vol. 9, no. 11, pp. 2110–2117, 1994.

[31] M. Amit, V. Margulets, H. Segev et al., “Human feeder layers for human embryonic stem cells,” *Biology of Reproduction*, vol. 68, no. 6, pp. 2150–2156, 2003.

[32] M. Richards, C.-Y. Fong, W.-K. Chan, P.-C. Wong, and A. Bongso, “Human feeders support prolonged undifferentiated growth of human inner cell masses and embryonic stem cells,” *Nature Biotechnology*, vol. 20, no. 9, pp. 933–936, 2002.

[33] J. Xi, Y. Wang, P. Zhang et al., “Human fetal liver stromal cells that overexpress hFGF support growth and maintenance of human embryonic stem cells,” *PLoS One*, vol. 5, no. 12, article e14457, 2010.

[34] L. Cheng, H. Hammond, Z. Ye, X. Zhan, and G. Dravid, “Human adult marrow cells support prolonged expansion of human embryonic stem cells in culture,” *Stem Cells*, vol. 21, no. 2, pp. 131–142, 2003.

[35] M. Cho, E. J. Lee, H. Nam et al., “Human feeder layer system derived from umbilical cord stromal cells for human embryonic stem cells,” *Fertility and Sterility*, vol. 93, no. 8, pp. 2525–2531, 2010.

[36] X. Gao, J. Yan, Y. Shen et al., “Human fetal trophoblasts matrix and uterine endometrium support better human embryonic stem cell growth and neural differentiation than mouse embryonic fibroblasts,” *Cell Reprogram*, vol. 12, no. 3, pp. 295–303, 2010.

[37] K. Miyamoto, K. Hayashi, T. Suzuki et al., “Human placenta feeder layers support undifferentiated growth of primate embryonic stem cells,” *Stem Cells*, vol. 22, no. 4, pp. 433–440, 2004.

[38] J. B. Lee, J. E. Lee, J. H. Park et al., “Establishment and maintenance of human embryonic stem cell lines on human feeder cells derived from uterine endometrium under serum-free condition,” *Biology of Reproduction*, vol. 72, no. 1, pp. 42–49, 2005.

[39] J. B. Lee, J. M. Song, J. E. Lee et al., “Available human feeder cells for the maintenance of human embryonic stem cells,” *Reproduction*, vol. 128, no. 6, pp. 727–735, 2004.

[40] C. Aguilar-Gallardo, M. Poo, E. Gomez et al., “Derivation, characterization, differentiation, and registration of seven human embryonic stem cell lines (VAL-3, -4, -5, -6M, -7, -8, and -9) on human feeder,” *In Vitro Cellular & Developmental Biology - Animal*, vol. 46, no. 3–4, pp. 317–326, 2010.

[41] K. Rajala, B. Lindroos, S. M. Hussein et al., “A defined and xeno-free culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells,” *PLoS One*, vol. 5, no. 4, article e10246, 2010.

[42] N. Desai, J. Xu, T. Tsuilaia et al., “Vitrification of mouse embryo-derived ICM cells: a tool for preserving embryonic stem cell potential,” *Journal of Assisted Reproduction and Genetics*, vol. 28, no. 2, pp. 93–99, 2011.

[43] H. F. Chen, C. Y. Chuang, Y. K. Shieh, H. W. Chang, H. N. Ho, and H. C. Kuo, “Novel autogenic feeders derived from human embryonic stem cells (hESCs) support an undifferentiated status of hESCs in xeno-free culture conditions,” *Human Reproduction*, vol. 24, no. 5, pp. 1114–1125, 2009.

[44] X. Fu, W. S. Toh, H. Liu et al., “Autologous feeder cells from embryoid body outgrowth support the long-term growth of human embryonic stem cells more effectively than those from direct differentiation,” *Tissue Engineering Part C: Methods*, vol. 16, no. 4, pp. 719–733, 2010.

[45] S. Park, K. S. Lee, Y. J. Lee et al., “Generation of dopaminergic neurons in vitro from human embryonic stem cells treated with neurotrophic factors,” *Neuroscience Letters*, vol. 359, no. 1-2, pp. 99–103, 2004.

[46] R. M. Albano, N. Groome, and J. C. Smith, “Activins are expressed in preimplantation mouse embryos and in ES and EC cells and are regulated on their differentiation,” *Development*, vol. 117, no. 2, pp. 711–723, 1993.

[47] L. Vallier, P. J. Rugg-Gunn, I. A. Bouhon, F. K. Andersson, A. J. Sadler, and R. A. Pedersen, “Enhancing and diminishing gene function in human embryonic stem cells,” *Stem Cells*, vol. 22, no. 1, pp. 2–11, 2004.

[48] S. N. Brimble, X. Zeng, D. A. Weiler et al., “Karyotypic stability, genotyping, differentiation, feeder-free maintenance, and gene expression sampling in three human embryonic stem cell lines derived prior to August 9, 2001,” *Stem Cells Development*, vol. 13, no. 6, pp. 585–597, 2004.

[49] S. Yao, S. Chen, J. Clark et al., “Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 18, pp. 6907–6912, 2006.

[50] J. A. Carlson Scholz, R. Garg, S. R. Compton, H. G. Allore, C. J. Zeiss, and E. M. Uchio, “Poliomyelitis in MuLV-infected ICR-SCID mice after injection of basement membrane matrix matrix contaminated with lactate dehydrogenase-elevating virus,” *Comparative Medicine*, vol. 61, no. 5, pp. 404–411, 2011.

[51] X. Fu, W. S. Toh, H. Liu, K. Lu, M. Li, and T. Cao, “A novel xeno-free and feeder-cell-free system for human pluripotent stem cell culture,” *Protein Cell*, vol. 3, no. 1, pp. 51–59, 2012.

[52] N. Desai, J. Ludgin, J. Goldberg, and T. Falcone, “Development of a xeno-free non-contact co-culture system for derivation
and maintenance of embryonic stem cells using a novel human endometrial cell line,” Journal of Assisted Reproduction and Genetics, vol. 30, no. 5, pp. 609–615, 2013.

[55] G. Pettinato, X. Wen, and N. Zhang, “Engineering strategies for the formation of embryoid bodies from human pluripotent stem cells,” Stem Cells and Development, vol. 24, no. 14, pp. 1595–1609, 2015.

[56] J. S. Odorico, D. S. Kaufman, and J. A. Thomson, “Multilineage differentiation from human embryonic stem cell lines,” Stem Cells, vol. 19, no. 3, pp. 193–204, 2001.

[57] G. Pettinato, X. Wen, and N. Zhang, “Formation of well-defined embryoid bodies from dissociated human induced pluripotent stem cells using microfabricated cell-repellent microwell arrays,” Scientific Reports, vol. 4, no. 1, p. 7402, 2014.

[58] H. Li, H. Zhou, X. Fu, and R. Xiao, “Directed differentiation of human embryonic stem cells into keratinocyte progenitors in vitro: an attempt with promise of clinical use,” In Vitro Cellular & Developmental Biology - Animal, vol. 52, no. 8, pp. 885–893, 2016.

[59] F. Yu, R. Wei, J. Yang et al., “FoxO1 inhibition promotes differentiation of human embryonic stem cells into insulin producing cells,” Experimental Cell Research, vol. 362, no. 1, pp. 227–234, 2018.

[60] E. Banda and L. Grabel, “Directed differentiation of human embryonic stem cells into neural progenitors,” Methods in Molecular Biology, vol. 1307, pp. 289–298, 2016.

[61] J. H. Oh, C. R. Jung, M. O. Lee, J. Kim, and M. Y. Son, “Comparative analysis of human embryonic stem cell-derived neural stem cells as an in vitro human model,” International Journal of Molecular Medicine, vol. 41, no. 2, pp. 783–790, 2018.

[62] J. A. Guadix, V. V. Orlova, E. Giacomelli et al., “Human pluripotent stem cell differentiation into functional epicardial progenitor cells,” Stem Cell Reports, vol. 9, no. 6, pp. 1754–1764, 2017.

[63] J. Chen, B. Tschudy-Seney, X. Ma, M. A. Zern, P. Liu, and Y. Duan, “Salvianolic acid B enhances hepatic differentiation of human embryonic stem cells through upregulation of WNT pathway and inhibition of Notch pathway,” Stem Cells and Development, vol. 27, no. 4, pp. 252–261, 2018.

[64] Y. Kim, H. Kim, U. H. Ko et al., “Islet-like organoids derived from human pluripotent stem cells efficiently function in the glucose responsiveness in vitro and in vivo,” Scientific Reports, vol. 6, no. 1, p. 35145, 2016.

[65] C. E. Murry and G. Keller, “Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development,” Cell, vol. 132, no. 4, pp. 661–680, 2008.

[66] I. Roberts, S. Baila, R. B. Rice et al., “Scale-up of human embryonic stem cell culture using a hollow fibre bioreactor,” Biotechnology Letters, vol. 34, no. 12, pp. 2307–2315, 2012.

[67] H. Hentze, R. Graichen, and A. Colman, “Cell therapy and the safety of embryonic stem cell-derived grafts,” Trends in Biotechnology, vol. 25, no. 1, pp. 24–32, 2007.

[68] T. Barberi, P. Klivenyi, N. Y. Calingsan et al., “Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice,” Nature Biotechnology, vol. 21, no. 10, pp. 1200–1207, 2003.

[69] S. Gerecht-Nir and J. Itskovitz-Eldor, “Human embryonic stem cells: a potential source for cellular therapy,” American Journal of Transplantation, vol. 4, pp. 51–57, 2004.

[70] J. Harding, R. M. Roberts, and O. Mirochnitchenko, “Large animal models for stem cell therapy,” Stem Cell Research & Therapy, vol. 4, no. 2, p. 23, 2013.

[71] X. Fu, “The immunogenicity of cells derived from induced pluripotent stem cells,” Cellular & Molecular Immunology, vol. 11, no. 1, pp. 14–16, 2014.

[72] A. Bongso, C. Y. Fong, and K. Gauthaman, “Taking stem cells to the clinic: major challenges,” Journal of Cellular Biochemistry, vol. 105, no. 6, pp. 1352–1360, 2008.

[73] R. Araki, M. Uda, Y. Hoki et al., “Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells,” Nature, vol. 494, no. 7435, pp. 100–104, 2013.

[74] T. Zhao, Z. N. Zhang, Z. Rong, and Y. Xu, “Immunogenicity of induced pluripotent stem cells,” Nature, vol. 474, no. 7350, pp. 212–215, 2011.

[75] I. Hyun, O. Lindvall, L. Åhrlund-Richter et al., “New ISSCR guidelines underscore major principles for responsible translational stem cell research,” Cell Stem Cell, vol. 3, no. 6, pp. 607–609, 2008.

[76] J. M. Crook, T. T. Peura, L. Kravets et al., “The generation of six clinical-grade human embryonic stem cell lines,” Cell Stem Cell, vol. 1, no. 5, pp. 490–494, 2007.

[77] C. Unger, H. Skottman, P. Blomberg, M. Sirac Dibler, and O. Hovatta, “Good manufacturing practice and clinical-grade human embryonic stem cell lines,” Human Molecular Genetics, vol. 17, no. R1, pp. R48–R53, 2008.

[78] H. S. Keirstead, G. Nistor, G. Bernal et al., “Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury,” Journal of Neuroscience, vol. 25, no. 19, pp. 4694–4705, 2005.

[79] J. Alper, “Geron gets green light for human trial of ES cell-derived product,” Nature Biotechnology, vol. 27, no. 3, pp. 213–214, 2009.

[80] L. A. Couture, “Scalable pluripotent stem cell culture,” Nature Biotechnology, vol. 28, no. 6, pp. 562-563, 2010.

[81] C. Geron, “World’s first clinical trial of human embryonic stem cell therapy cleared,” Regenerative Medicine, vol. 4, no. 2, p. 161, 2009.

[82] E. Ratchiffe, K. E. Glen, M. W. Naing, and D. J. Williams, “Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies,” British Medical Bulletin, vol. 108, no. 1, pp. 73–94, 2013.

[83] S. D. Schwartz, J. P. Hubschman, G. Heilwell et al., “Embryonic stem cell trials for macular degeneration: a preliminary report,” Lancet, vol. 379, no. 9817, pp. 713–720, 2012.

[84] S. Strauss, “Geron trial resumes, but standards for stem cell trials remain elusive,” Nature Biotechnology, vol. 28, no. 10, pp. 989-990, 2010.

[85] A. Trounson, R. G. Thakar, G. Lomax, and D. Gibbons, “Clinical trials for stem cell therapies,” BMC Medicine, vol. 9, no. 1, p. 52, 2011.

[86] P. Laikind, “Via Cyte, Inc. announces FDA acceptance of IND to commence clinical trial of VC-01™ candidate cell replacement therapy for type 1 diabetes,” 2014, August 2014 http://vicyte.com/press-releases/vicyte-inc-announces-fda-acceptance-of-ind-to-commence-clinical-trial-of-vc-01-candidate-cell-replacement-therapy-for-type-1-diabetes/.